Clinical trial
Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance
NCT00237250 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00237250 |
|---|---|
| Title | Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance |
| Official title | Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prediabetic State |
| Intervention type | Drug |
| Interventions | vildagliptin |
| Enrollment | 171 |
| Start date | Oct 1, 2005 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Oct 12, 2005 |
| Last update posted | May 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: